Angiotensin-(1–7) and Bradykinin in Norepinephrine Release in the Central Nervous System of Hypertension

To the Editor:

We read with great interest the recent article by Dr Gironacci and colleagues1 dealing with the sympatholytic action of angiotensin (Ang)-(1–7) in the central nervous system of spontaneously hypertensive rats (SHR). The results of their study demonstrated that Ang-(1–7) decreased the K⁺-induced norepinephrine (NE) release in the hypothalamus of SHR by stimulating the angiotensin type-2 (AT₂) receptors, which might be consistent with their previous report.2 In addition, they indicated that the inhibitory effect of Ang-(1–7) on NE release was blocked by the nitric oxide (NO) synthase inhibitor N⁴-nitro-L-arginine methyl ester and bradykinin (BK) B₂ receptor antagonist icatibant. The authors proposed that Ang-(1–7) reduced NE release from the hypothalamus of SHR via the AT₂ receptors, acting through a BK/NO-mediated mechanism.

Several studies have reported the possible mechanisms of altered NE release in the central nervous system of hypertension.3–5 In a study we presented earlier, the change in NE release induced by BK was investigated in the hypothalamus of normotensive and hypertensive rats.6,7 In an in vitro study using rat brain slices, we showed that BK increased the stimulation-evoked NE release in a dose-dependent manner. It was also demonstrated that a dihydropyridine (DHP)-sensitive calcium (Ca) channel agonist Bay K 8644 significantly potentiated the facilitatory effect of BK on NE release. In contrast, nicardipine, a DHP-sensitive Ca channel blocker, reversed the increase in NE release induced by BK and Bay K 8644. The finding might indicate a possible interaction of BK with DHP-sensitive Ca channels in the central nervous system of hypertension. Recently, it has been shown that BK might increase the intracellular Ca concentration via intracellular Ca-release and extracellular Ca-influx through the transduction of G protein in PC 12 cells.8 It can be speculated that multiple signal transduction pathways may be associated with the effects of BK.9 Therefore, we would like to know whether BK itself might have a synergistic effect with Ang-(1–7) on NE release in the hypothalamus of SHR in the present study of Dr Gironacci and colleagues. Further studies should be performed to assess more thoroughly the relationships between Ang-(1–7) and BK and their role in the regulation of central sympathetic nerve activity in hypertension.

Kazushi Tsuda
Ichiro Nishio

Division of Cardiology, Department of Medicine
Wakayama Medical University
Wakayama, Japan


Response:

I read with interest Tsuda’s letter to the editor about our work. Measurement of kinin peptides gives important information about the functioning of the kallikrein-kinin system. Campbell et al. have demonstrated that bradykinin (BK) levels in the brain of spontaneously hypertensive rats are similar to those found in normotensive rats, being ~6.5 fmol/g tissue in 10-week-old rats and 12.1 fmol/g tissue in 20-week-old rats.1,2 Tsuda et al. showed that high concentrations of BK (1 and 3.3 μmol/L) induced a 20% to 30% increase in stimulation-evoked [3H]norepinephrine (NE) release from hypothalamic slices of normotensive rats, that is, BK seems to exert a facilitative effect on NE release at the central level only at pharmacological dosis. In our study, when we used icatibant to block the endogenous formation of BK, the inhibitory effect of Ang-(1–7) on NE release disappeared, suggesting BK involvement. In addition, the inhibitory effect of Ang-(1–7) was also blocked in the presence of an inhibitor of nitric oxide synthesis, suggesting that endogenous BK is mediating nitric oxide release, and in this way Ang-(1–7) diminishes NE release. Therefore, since central endogenous levels of BK are very low, a synergistic effect between BK and Ang-(1–7) on NE release is not expected, as Dr Tsuda suggested. On the other hand, synergy means “working together”, so we would not expect to see a synergistic effect between Ang-(1–7) and BK on NE release when they have an antagonistic effect on that mechanism. Furthermore, adding exogenous peptides such as BK has limitations: Not only do the concentrations added fail to mimic endogenous levels, but also these exogenous concentrations of BK may not mimic the site of release and action of endogenous kinins because these peptides act mainly as autocrine (at the site of release) and paracrine autacoids (near the site of release) and not as endocrine hormones.

Mariela M. Gironacci
Departamento de Quimica Biologica
Instituto de Quimica y Fisicoquimica Biologicas
Facultad de Farmacia y Bioquimica
Universidad de Buenos Aires, Argentina
Angiotensin-(1–7) and Bradykinin in Norepinephrine Release in the Central Nervous System of Hypertension
Kazushi Tsuda and Ichiro Nishio

Hypertension. 2005;45:e8; originally published online January 3, 2005;
doi: 10.1161/01.HYP.0000154192.64972.b8
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/45/2/e8

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/